Astrotech (ASTC) AI Stock Analysis

• Market Cap: $9.90M
• Dividend Yield: N/A
• Average Volume (3M): 2.77K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.52
• Revenue Growth: -78.93%
• EPS Growth: -29.96%
• Country: US
• Employees: 30
• Sector: Industrials
• Sector Strength: 78
• Industry: Aerospace & Defense
• EPS (TTM): -8.13
• Shares Outstanding: 1,701,729
• 10 Day Avg. Volume: 2,005
• 30 Day Avg. Volume: 2,772
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• Price to Cash Flow (P/CF): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: -1.52
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -20.05
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Astrotech's overall stock score is low due to significant financial challenges, including persistent losses and liquidity issues. The technical analysis indicates weak momentum, while valuation metrics reflect the company's struggle for profitability. Despite these challenges, recent corporate events offer potential for future growth, but they are not enough to offset the current financial and technical weaknesses.

Astrotech Business Overview & Revenue Model

Company Description

Astrotech Corporation (ASTC) is a technology company primarily focused on developing, commercializing, and marketing innovative scientific and technical advancements for a variety of applications. Operating in sectors such as aerospace, defense, and biotechnology, Astrotech provides essential products and services that cater to both government and commercial clientele. The company's core offerings include its subsidiary operations in mass spectrometry technology and space technology solutions.

How the Company Makes Money

Astrotech Corporation generates revenue through several main channels. One of its primary revenue streams is derived from its subsidiary, 1st Detect Corporation, which specializes in the development and sale of mass spectrometry instruments used for chemical detection and analysis. These instruments are utilized in a range of industries, including security, healthcare, and environmental monitoring. Additionally, Astrotech's space-related services and products, offered through Astrotech Space Operations, contribute to its income by providing support for satellite and spacecraft launch preparations. The company also benefits from strategic partnerships and contracts with government agencies and private sector companies, leveraging its technological expertise and solutions to secure long-term engagements that provide a stable source of revenue.

Astrotech Financial Statement Overview

Summary

Astrotech faces severe financial challenges, with negative margins and inconsistent revenue growth. The balance sheet is slightly stabilized by high equity, but cash flow issues indicate ongoing liquidity concerns.

Income Statement

Astrotech's income statement reveals significant weaknesses, with a negative gross profit margin of -9.79% and a continuously negative net profit margin. The revenue growth rate has been inconsistent, with a notable decline in the TTM. The EBIT and EBITDA margins are deeply negative, indicating ongoing operational and profitability challenges.

Balance Sheet

The balance sheet shows a relatively strong equity position with an equity ratio of 90.65%. However, the company's high leverage is a concern, reflected in a debt-to-equity ratio of 0.0051. Return on Equity is negative due to consistent net losses, indicating inefficiency in generating returns on equity.

Cash Flow

Astrotech's cash flow statement highlights significant challenges, with negative operating cash flow and free cash flow. The operating cash flow to net income ratio is negative, indicating cash utilization issues. Free cash flow growth has been erratic, underscoring financial instability.

Breakdown
Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement		Total Revenue
1.66M	750.00K	869.00K	334.00K	488.00K
	Gross Profit
751.00K	306.00K	192.00K	36.00K	39.00K
	EBIT
-13.28M	-11.06M	-8.60M	-7.40M	-8.11M
	EBITDA
-12.41M	-10.69M	-8.36M	-7.31M	-7.58M
	Net Income Common Stockholders
-11.67M	-9.64M	-7.56M	-7.61M	-8.51M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
31.92M	42.13M	52.63M	63.29M	3.35M
	Total Assets
37.64M	47.67M	56.22M	65.63M	5.93M
	Total Debt
300.00K	607.00K	1.04M	2.80M	4.00M
	Net Debt
-10.14M	-13.60M	-25.42M	-33.14M	655.00K
	Total Liabilities
2.83M	2.96M	2.98M	4.43M	5.30M
	Stockholders Equity
34.81M	44.72M	53.24M	61.21M	625.00K
Cash Flow		Free Cash Flow
-10.30M	-9.47M	-7.39M	-7.62M	-6.93M
	Operating Cash Flow
-9.72M	-7.63M	-6.79M	-7.41M	-6.93M
	Investing Cash Flow
6.14M	-3.84M	-596.00K	-27.59M	0.00
	Financing Cash Flow
-181.00K	-776.00K	-2.10M	67.58M	8.69M

Astrotech Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 5.82
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ASTC, the sentiment is Negative. The current price of 5.82 is below the 20-day moving average (MA) of 5.99, below the 50-day MA of 6.27, and below the 200-day MA of 7.43, indicating a bearish trend. The MACD of -0.13 indicates Negative momentum. The RSI at 38.86 is Neutral, neither overbought nor oversold. The STOCH value of 26.61 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ASTC.

Astrotech Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	63 Neutral	$4.21B	11.55	5.28%	250.72%	4.13%	-9.42%
XTIA	45 Neutral	$7.58M	―	-552.16%	―	―	―
SIDU	42 Neutral	$28.92M	―	-114.28%	―	-21.64%	86.28%
MNTS	38 Underperform	$9.67M	―	688.16%	―	-31.56%	94.00%
ASTC	36 Underperform	$9.90M	―	-39.20%	―	-78.93%	-29.96%
PRZO	30 Underperform	$14.43M	―	-370.62%	―	49.04%	-121.30%

Astrotech Corporate Events

Astrotech Launches Enhanced TRACER 1000 Narcotics Detector

On March 10, 2025, Astrotech Corporation announced the launch of the enhanced TRACER 1000™ Narcotics Trace Detector from its 1st Detect subsidiary. This advanced mass spectrometer is designed to detect synthetic opiates and novel psychoactive substances, offering a significant improvement in portable trace detection. The TRACER 1000 NTD aims to aid law enforcement, border security, and public health agencies in addressing the global synthetic drug crisis by providing rapid and precise identification of illicit substances. The device’s enhanced capabilities could help authorities prevent dangerous drugs from reaching communities, thus positioning Astrotech as a key player in the fight against synthetic drug trafficking.